International Assets Investment Management LLC Raises Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

International Assets Investment Management LLC increased its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 59,222.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 75,933 shares of the biotechnology company’s stock after acquiring an additional 75,805 shares during the quarter. International Assets Investment Management LLC’s holdings in Sarepta Therapeutics were worth $9,483,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SRPT. Nordea Investment Management AB boosted its stake in Sarepta Therapeutics by 120.6% during the 1st quarter. Nordea Investment Management AB now owns 61,657 shares of the biotechnology company’s stock worth $8,004,000 after purchasing an additional 33,711 shares during the last quarter. Fifth Third Wealth Advisors LLC acquired a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at about $607,000. Teachers Retirement System of The State of Kentucky acquired a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at about $4,771,000. Securian Asset Management Inc. acquired a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at about $1,187,000. Finally, Natixis Advisors LLC acquired a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at about $1,918,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insider Transactions at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, Director Michael Andrew Chambers bought 37,038 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the purchase, the director now owns 284,034 shares of the company’s stock, valued at $38,003,749.20. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on SRPT. Piper Sandler decreased their target price on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Jefferies Financial Group assumed coverage on shares of Sarepta Therapeutics in a research note on Monday, October 21st. They set a “buy” rating and a $165.00 target price on the stock. Raymond James reaffirmed an “outperform” rating and issued a $150.00 target price on shares of Sarepta Therapeutics in a report on Thursday, October 10th. Evercore ISI raised shares of Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and cut their price objective for the stock from $185.00 to $179.00 in a report on Thursday, August 8th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $152.00 price objective on shares of Sarepta Therapeutics in a report on Friday, September 20th. Two investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $182.95.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $127.78 on Thursday. The firm has a market capitalization of $12.08 billion, a P/E ratio of 1,161.64 and a beta of 0.82. Sarepta Therapeutics, Inc. has a one year low of $55.25 and a one year high of $173.25. The company’s fifty day moving average is $128.07 and its two-hundred day moving average is $132.57. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.90.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.01 by $0.06. The company had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The business’s revenue was up 38.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.27) EPS. Analysts forecast that Sarepta Therapeutics, Inc. will post 1.45 EPS for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.